SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Amyloid beta-peptide (Abeta) deposition in cerebral vessels contributes to cerebral amyloid angiopathy (CAA) in Alzheimer's disease (AD). Here, we report that in AD patients and two mouse models of AD, overexpression of serum response factor (SRF) and myocardin (MYOCD) in cerebral vascular smooth muscle cells (VSMCs) generates an Abeta non-clearing VSMC phenotype through transactivation of sterol regulatory element binding protein-2, which downregulates low density lipoprotein receptor-related protein-1, a key Abeta clearance receptor. Hypoxia stimulated SRF/MYOCD expression in human cerebral VSMCs and in animal models of AD. We suggest that SRF and MYOCD function as a transcriptional switch, controlling Abeta cerebrovascular clearance and progression of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the low-density lipoprotein receptor–related protein-1, a critical Aβ brain clearance receptor, is downregulated in cerebral blood vessels of patients with Alzheimer disease, leading to accumulation of amyloid around blood vessels and worsening of vascular dysfunction.129”
From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“In particular, suppression of LRP1 in vascular smooth muscle cells due to upregulation of serum response factor and myocardin, is a key factor in the clearance impairment (Bell et al., 2009).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Bell et al., 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“dtd" [ ]> Dementia in Alzheimer's disease (AD) is associated with neurovascular dysfunctio”
Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline
Vermeer, S. E., Prins, N. D., den Heijer, T., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022066 · Cited by 2,313
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213 · cited 1×
“dtd" [ ]> Dementia in Alzheimer's disease (AD) is associated with neurovascular dysfunctio”
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“The low-density lipoprotein receptor-related protein 1 (LRP) is a major Aβ clearance receptor at the BB”
BackgroundWolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398 · cited 1×
“Previous studies have shown that people chronically treated with cholesterol-lowering drugs, such as statins, are less prone to develop A”
BackgroundAdult mouse astrocytes degrade amyloid-β in vitro and in situ
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., & Husemann, J. (2003) · Nature Medicine · doi:10.1038/nm838 · Cited by 909
Wang, D.-Z., Chang, P. S., Wang, Z., Sutherland, L., Richardson, J. A., Small, E., Krieg, P. A., & Olson, E. N. (2001) · Cell · doi:10.1016/s0092-8674(01)00404-4 · Cited by 898
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Self-citation
Research works printed but not linked: 1
- Holtzman, D. M. et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47, 739–747 (2000). · doi:10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Self-citationA molecular atlas of cell types and zonation in the brain vasculature
Vanlandewijck, M., He, L., Mäe, M. A., Andrae, J., Ando, K., Del Gaudio, F., Nahar, K., Lebouvier, T., Laviña, B., Gouveia, L., et al. (2018) · Nature · doi:10.1038/nature25739 · Cited by 1,892
The Science of Stroke: Mechanisms in Search of Treatments
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.07.002 · Cited by 1,930
The Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
Bell, R. D., Winkler, E. A., Sagare, A. P., Singh, I., LaRue, B., Deane, R., & Zlokovic, B. V. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.043 · Cited by 1,448
“Perfusion stress and BBB compromise have been associated with neurodegenerative disorders (Zlokovic, 2008), including Alzheimer’s disease (Iadecola et al., 1999; Deane et al., 2003; Chow et al., 2007; Bell et al., 2009) and amyotrophic lateral sclerosis (Zhong et al., 2008, 2009; Rule et al., 2010).”
BackgroundMethodInfluentialSelf-citationCerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease
Kisler, K., Nelson, A. R., Montagne, A., & Zlokovic, B. V. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.48 · Cited by 1,243
Central nervous system pericytes in health and disease
Winkler, E. A., Bell, R. D., & Zlokovic, B. V. (2011) · Nature Neuroscience · doi:10.1038/nn.2946 · Cited by 962
Self-citationLinking actin dynamics and gene transcription to drive cellular motile functions
Olson, E. N., & Nordheim, A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2890 · Cited by 958
Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
Bell, R. D., & Zlokovic, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 860
“Recently, CAA-positive cerebral blood vessels isolated from AD patients have also been shown to have a significant increase in MYOCD and SRF levels [8] confirming the above findings.”
BackgroundResultSelf-citationThe blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767
“…to the development of several CNS pathologies, including dementia, thus promoting neurode-generation and cognitive decline during aging and in AD (Deane and Zlokovic, 2007; Lok et al., 2007; Neuwelt et al., 2008; Bell and Zlokovic, 2009; Bell et al., 2010; Zlokovic, 2011; Erickson and Banks, 2013).”
The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles
Lacolley, P., Regnault, V., Nicoletti, A., Li, Z., & Michel, J.-B. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs135 · Cited by 701
“Regulation of the expression level of these transcription factors drives the effects of antiproliferative molecules such as adiponectin, TGF-b, and peroxisome proliferator-activated receptor gamma (PPAR-g).34 miRs dynamically regulate VSMC differentiation and phenotypic switching. miR-143/145, miR-21, and miR-1 promot…”
BackgroundInfluentialGLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration
Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., Sengillo, J. D., Hillman, S., Kong, P., Nelson, A. R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3966 · Cited by 689
Self-citationAlzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672
Cerebral amyloid angiopathy in the elderly
Viswanathan, A., & Greenberg, S. M. (2011) · Annals of Neurology · doi:10.1002/ana.22516 · Cited by 643
“Accelerated vascular deposition of Ab may occur through transcriptional regulation of the lipoprotein receptor LRP in vascular smooth muscle due to overexpression of the transcription factors serum response factor (SRF) and myocardin.(7) Additionally, SRF and myocardin may also regulate contractile proteins in vascula…”
BackgroundDeane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619
“At pathophysiological levels, A β accelerates neurovascular (10, 16) and neuronal (17–19) dysfunction and self propagates (11, 20, 21), as in prion disease (22), leading to the development of cerebral β -amyloidosis (23).”
Self-citationApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
Self-citationRetractedThe dynamic blood–brain barrier
Keaney, J., & Campbell, M. (2015) · The FEBS Journal · doi:10.1111/febs.13412 · Cited by 616
Saxena, S., & Caroni, P. (2011) · Neuron · doi:10.1016/j.neuron.2011.06.031 · Cited by 572
Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
“Concomitant vascular abnormalities CAA, basement membrane abnormalities, string vessel formation, microinfarcts, arteriosclerosis, and/or atherosclerosis, are frequently observed in MCI and AD patients [94] and in post-mortem AD brain tissue [95].”
BackgroundInfluentialSelf-citationThe overlap between neurodegenerative and vascular factors in the pathogenesis of dementia
Iadecola, C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0718-6 · Cited by 557
“Intracerebral Ab, normally produced by synaptic activity [15], is cleared from the brain through vascular mechanisms involving the lipoprotein receptor protein 1 (LRP1) and P-glycoprotein, a process controlled by the serum response factor and myocardin [8, 14, 93].”
Verghese, P. B., Castellano, J. M., Garai, K., Wang, Y., Jiang, H., Shah, A., Bu, G., Frieden, C., & Holtzman, D. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220484110 · Cited by 556
“Studies have shown that LRP1 is involved in the metabolism of Aβ in the brain by directly binding to Aβ for cellular uptake/clearance or indirectly through other pathways (73-75).”
BackgroundDeane, R., Bell, R., Sagare, A., & Zlokovic, B. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601867 · Cited by 548
“In this new concept, dementia in AD is associated with cerebrovascular disorder [13,17-20], which leads to accumulation of Aβ on blood vessels (cerebral amyloid angiapothy, CAA) and in the brain parenchyma, extracellular deposits [9,13,21,22], and intraneuronal lesions - neurofibrillar tangles [23].”
BackgroundSelf-citationProteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
“A can be taken up by smooth muscle cells delineating the arterioles or by endothelial cells that participate in the blood-brain barrier (19, 20, 64, 104, 366).”
BackgroundCentral role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance
Zhao, Z., Sagare, A. P., Ma, Q., Halliday, M. R., Kong, P., Kisler, K., Winkler, E. A., Ramanathan, A., Kanekiyo, T., Bu, G., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4025 · Cited by 410
Self-citationPericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss
Nikolakopoulou, A. M., Montagne, A., Kisler, K., Dai, Z., Wang, Y., Huuskonen, M. T., Sagare, A. P., Lazic, D., Sweeney, M. D., Kong, P., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0434-z · Cited by 391
“…were confirmed to be morphologically consistent with VSMC cultures and were SMA-positive, calponin-positive, SM22 α -positive, von Willebrand factor-negative, GFAP-negative, AQP4-negative, MAP2-negative, NeuN-negative, Iba1-negative, and prolyl-4-hydroxylase-negative, as we previously reported 59 .”
Self-citationBrain Pericytes As Mediators of Neuroinflammation
Rustenhoven, J., Jansson, D., Smyth, L. C., & Dragunow, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.001 · Cited by 371
Cholesterol: its regulation and role in central nervous system disorders
Orth, M., & Bellosta, S. (2012) · Cholesterol · doi:10.1155/2012/292598 · Cited by 339
“Numerous lipoprotein receptors of the LDL receptor family have been detected in the CNS by biochemical and molecular methods (LDL receptor, VLDL-receptor, apoER2/LRP8, LRP4, LRP, LRP2 (formerly known as gp330 or megalin), LRP1B, LRP5/LRP6, and LRP11/SORL1) [13, 159].”
BackgroundInfluentialShinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075796 · Cited by 297
Ma, Q., Zhao, Z., Sagare, A. P., Wu, Y., Wang, M., Owens, N. C., Verghese, P. B., Herz, J., Holtzman, D. M., & Zlokovic, B. V. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0286-0 · Cited by 281
Self-citationKanekiyo, T., & Bu, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00093 · Cited by 281
“In leptomeningeal arteries from AD patients with CAA, Western blot analysis revealed elevated Aβ levels and lower levels of LRP1 compared with age-matched, non-demented controls (Bell et al., 2009).”
BackgroundThe Pericyte: A Forgotten Cell Type with Important Implications for Alzheimer's Disease?
Winkler, E. A., Sagare, A. P., & Zlokovic, B. V. (2014) · Brain Pathology · doi:10.1111/bpa.12152 · Cited by 278
“For example, studies in both human AD subjects and transgenic models have demonstrated upregulation of two transcription factors, myocardin (MYOCD) and serum response factor (SRF), important for controlling vSMC differentiation and leads to upregulation of vSMC contractile proteins, a hypercontractile vSMC phenotype,…”
InfluentialSelf-citationGovindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
“In both AD-derived human vSMCs and in AD mouse models, it was reported that the transcription factors serum response factor (SRF) and myocardin (MYOCD) are significantly upregulated within vSMCs [272], resulting in Aβ clearance deficits through the expression of sterol regulatory element binding protein-2 (SREBP2) and…”
BackgroundNishitsuji, K., Hosono, T., Nakamura, T., Bu, G., & Michikawa, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.225532 · Cited by 275
Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261
Self-citationThe neurovascular link in health and disease: molecular mechanisms and therapeutic implications
Quaegebeur, A., Lange, C., & Carmeliet, P. (2011) · Neuron · doi:10.1016/j.neuron.2011.07.013 · Cited by 247
“Ab clearance is further compromised due to the vasoconstriction by hypercontractile SMCs and to the reduced endothelial LRP-1 expression, both resulting from overexpression of MyoCD and SRF (Bell et al., 2009; Chow et al., 2007).”
InfluentialReal-Time In Vivo Imaging Reveals the Ability of Monocytes to Clear Vascular Amyloid Beta
Michaud, J.-P., Bellavance, M.-A., Préfontaine, P., & Rivest, S. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.010 · Cited by 257
“Thus far, the main pathways of Ab elimination involve phagocytosis and proteolytic degradation by mononuclear and vascular smooth muscle cells, transcytosis across the blood-brain barrier (BBB), and perivascular lymphatic drainage (Bell et al., 2009; Deane et al., 2009; Weller et al., 2009).”
BackgroundNeurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251
“2009), and it has been shown that it is also upstream of elevated MYOCD/SRF expression in cerebral arterial VSMCs (Bell et al. 2009).”
BackgroundSelf-citationHartz, A. M. S., Bauer, B., Soldner, E. L. B., Wolf, A., Boy, S., Backhaus, R., Mihaljevic, I., Bogdahn, U., Klünemann, H. H., Schuierer, G., et al. (2012) · Stroke · doi:10.1161/strokeaha.111.627562 · Cited by 248
Clusterin: A forgotten player in Alzheimer's disease
Nuutinen, T., Suuronen, T., Kauppinen, A., & Salminen, A. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.007 · Cited by 267
Brain microvascular pericytes in health and disease
Dalkara, T., Gursoy-Ozdemir, Y., & Yemisci, M. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0847-6 · Cited by 226
LRP1 in Brain Vascular Smooth Muscle Cells Mediates Local Clearance of Alzheimer's Amyloid-β
Kanekiyo, T., Liu, C.-C., Shinohara, M., Li, J., & Bu, G. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3987-12.2012 · Cited by 211
“…muscle cell layer of the cerebral blood vessels (Zlokovic, 2011) and its expression is vastly decreased in the vasculature of AD brains with CAA (Bell et al., 2009), we sought to examine whether LRP1 in vascular smooth muscle cells mediates local clearance of A , and whether a disturbance of…”
BackgroundResultInfluentialLin, A.-L., Zheng, W., Halloran, J. J., Burbank, R. R., Hussong, S. A., Hart, M. J., Javors, M., Shih, Y.-Y. I., Muir, E., Fonseca, R. S., et al. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.82 · Cited by 208
Ramanathan, A., Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00136 · Cited by 205
“On the other hand, two other interrelated transcriptional factors constituting the critical regulators of VSMCs differentiation, namely, serum response factor (SRF) and myocardin (MYOCD) are, in turn, upregulated in AD (Chow et al., 2007; Bell et al., 2009).”
BackgroundInfluentialSelf-citationCerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases
Grammas, P., Martinez, J., & Miller, B. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001918 · Cited by 202
The capillary dysfunction hypothesis of Alzheimer's disease
Østergaard, L., Aamand, R., Gutiérrez-Jiménez, E., Ho, Y.-C. L., Blicher, J. U., Madsen, S. M., Nagenthiraja, K., Dalby, R. B., Drasbek, K. R., Møller, A., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.09.011 · Cited by 199
“First, the upregulation of HIF-1 stimulates the expression of both human and animal amyloid precursor protein cleavage enzyme, which leads to an increased production of Ab (Sun et al., 2006; Zhang and Le, 2010).”
InfluentialBlood-brain barrier and cerebral small vessel disease
Wardlaw, J. M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.08.042 · Cited by 198
“This in turn is thought to result in reduced clearance of amyloid beta-peptide with accumulation of amyloid in the arteriolar walls leading to cerebral amyloid angiopathy and microbleeds [31].”
Pathological role of hypoxia in Alzheimer's disease
Zhang, X., & Le, W. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.033 · Cited by 188
“Hypoxia may be an initial stimulus for MYOCD and SRF upregulation in hypoxic cerebral VSMCs, which may attribute to the reduction in CBF and Aβ clearance from brain (Bell et al., 2009; Chow et al., 2007, Reynolds et al., 2004).”
BackgroundInfluentialHow Do Meningeal Lymphatic Vessels Drain the CNS?
Raper, D., Louveau, A., & Kipnis, J. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.07.001 · Cited by 179
“Macromolecules, such as amyloid beta (Ab), are supposedly cleared from the CNS parenchyma via different mechanisms, such as phagocytosis and proteolytic degradation by mononuclear phagocytes [35–37] and vascular smooth muscle cells [38], transcytosis across the blood–brain barrier (BBB) [39–41] and via ISF bulk flow […”
BackgroundHawkes, C. A., Sullivan, P. M., Hands, S., Weller, R. O., Nicoll, J. A. R., & Carare, R. O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041636 · Cited by 180
“Recent work has demonstrated an important role for serum response factor and myocardin in regulating LRP-1 levels in cerebral vascular smooth muscle cells, which are also involved in Ab clearance [51].”
BackgroundPatel, J. P., & Frey, B. N. (2015) · Neural Plasticity · doi:10.1155/2015/708306 · Cited by 177
“Numerous studies using both animal models and human patients with AD show that Aβ clearance is impaired in these cases [49–53].”
BackgroundMore than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration
Lane-Donovan, C., Philips, G. T., & Herz, J. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.005 · Cited by 158
“Smooth muscle cell levels of Lrp1 are reduced in AD (Bell et al., 2009).”
Role of serum response factor in the pathogenesis of disease
Miano, J. M. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.104 · Cited by 177
“Furthermore, increases in SRF were recently shown to impede the normal clearance of amyloid b-peptides through direct activation of SREBP2, a known repressor of the major amyloid b clearance receptor, LRP1.(86) Thus, SRF has emerged as a putative target for therapeutic intervention of this devastating disease that is…”
Self-citationDorr, A., Sahota, B., Chinta, L. V., Brown, M. E., Lai, A. Y., Ma, K., Hawkes, C. A., McLaurin, J., & Stefanovic, B. (2012) · Brain · doi:10.1093/brain/aws243 · Cited by 153
Fernández, A., Llacuna, L., Fernández-Checa, J. C., & Colell, A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4909-08.2009 · Cited by 153
Meng, X.-F., Yu, J.-T., Wang, H.-F., Tan, M.-S., Wang, C., Tan, C.-C., & Tan, L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140954 · Cited by 150
Functional versatility of transcription factors in the nervous system: the SRF paradigm
Knöll, B., & Nordheim, A. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.05.004 · Cited by 179
Erickson, M. A., Hartvigson, P. E., Morofuji, Y., Owen, J. B., Butterfield, D. A., & Banks, W. A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-150 · Cited by 145
“and vascular smooth muscle cells could contribute to vascular partitioning [60,61] because these cells remain”
BackgroundNeurovascular Defects and Faulty Amyloid-β Vascular Clearance in Alzheimer's Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129037 · Cited by 140
“In addition, it has been shown that increased levels of MYOCD and SRF in AD VSMCs also suppress Aβ clearance directly thus further exacerbating CAA [37].”
InfluentialSelf-citationSagare, A. P., Deane, R., & Zlokovic, B. V. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.008 · Cited by 143
“…risk factors and/or develop vascular changes in brain (i.e., > 65% of cases over the age of 60 and > 85% of cases over 80) (Wu et al., 2005; Bell et al., 2009; Zlokovic, 2011), it remains elusive whether MCI patients who later develop vascular dementia without amyloid deposition can also…”
BackgroundInfluentialSelf-citationStorck, S. E., Hartz, A. M. S., Bernard, J., Wolf, A., Kachlmeier, A., Mahringer, A., Weggen, S., Pahnke, J., & Pietrzik, C. U. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.07.017 · Cited by 143
Shedding of soluble platelet-derived growth factor receptor-β from human brain pericytes
Sagare, A. P., Sweeney, M. D., Makshanoff, J., & Zlokovic, B. V. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.09.025 · Cited by 142
Self-citationLRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier
Pflanzner, T., Janko, M. C., André-Dohmen, B., Reuss, S., Weggen, S., Roebroek, A. J. M., Kuhlmann, C. R. W., & Pietrzik, C. U. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.025 · Cited by 141
Myocardin in biology and disease
(2015) · Journal of biomedical research · doi:10.7555/jbr.29.20140151 · Cited by 138
“induce MYOCD in human cerebral SMC as well as rodent SMC [141] .”
BackgroundInfluentialSelf-citationThe Neurovascular Unit Dysfunction in Alzheimer’s Disease
Soto-Rojas, L. O., Pacheco-Herrero, M., Martínez-Gómez, P. A., Campa-Córdoba, B. B., Apátiga-Pérez, R., Villegas-Rojas, M. M., Harrington, C. R., de la Cruz, F., Garcés-Ramírez, L., & Luna-Muñoz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042022 · Cited by 136
Yew, B., Nation, D. A., & Initiative, F. T. A. D. N. (2017) · Brain · doi:10.1093/brain/awx112 · Cited by 133
“Reduced clearance ability consequently instigates accumulation of amyloid, leading to plaque formation and/or increased risk of white matter lesions that can further promote Alzheimer’s symptomatology (Qiu et al., 2005; Bell et al., 2009; Weller et al., 2009).”
Langbaum, J. B. S., Chen, K., Launer, L. J., Fleisher, A. S., Lee, W., Liu, X., Protas, H. D., Reeder, S. A., Bandy, D., Yu, M., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.020 · Cited by 133
“Results from recent molecular studies suggest that circulatory defects, such as those caused by stiffening of the vasculature system, may result in failure of clearance of Aβ from the brain (Bell et al., 2009).”
BackgroundInfluentialScioli, M., Bielli, A., Arcuri, G., Ferlosio, A., & Orlandi, A. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-19 · Cited by 132
“The accelerated β-amyloid vascular deposition in CAA seems to be caused by a transcriptional deregulation of the lipoprotein receptor LRP in VSMCs due to overexpression of the transcription factors: serum response factor (SRF) and myocardin [105].”
Alzheimer's Mechanisms in Ischemic Brain Degeneration
Pluta, R., Ułamek, M., & Jabłoński, M. (2009) · The Anatomical Record · doi:10.1002/ar.21018 · Cited by 133
“…suggest that translocation to and accumulation of b-amyloid peptide in the brain and in the cerebral vessels require dysfunction of the blood-brain barrier (Pluta et al., 1996; Dickstein et al., 2006) and downregulation of low-density lipoprotein receptor-related protein-1 (Bell et al., 2009).”
BackgroundInfluentialLong, X., & Miano, J. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.258814 · Cited by 132
Self-citationInnate immunity receptor CD36 promotes cerebral amyloid angiopathy
Park, L., Zhou, J., Zhou, P., Pistick, R., El Jamal, S., Younkin, L., Pierce, J., Arreguin, A., Anrather, J., Younkin, S. G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300021110 · Cited by 130
“LRP-1 down-regulation reduces brain-to-blood Aβ transport and promotes Aβ accumulation (42), whereas its upregulation facilitates brain-to-blood Aβ clearance (43).”
BackgroundMyocardin Regulates Vascular Smooth Muscle Cell Inflammatory Activation and Disease
Ackers-Johnson, M., Talasila, A., Sage, A. P., Long, X., Bot, I., Morrell, N. W., Bennett, M. R., Miano, J. M., & Sinha, S. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.305218 · Cited by 129
Self-citationProtection after stroke: cellular effectors of neurovascular unit integrity
Posada-Duque, R. A., Barreto, G. E., & Cardona-Gomez, G. P. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00231 · Cited by 123
“…the rupture of the BBB, the loss of brain blood flow regulation, oxidative stress, inflammation, and the loss of neuronal connections, ultimately increasing brain dysfunction (Deane et al., 2003; Ohab et al., 2006; Konsman et al., 2007; Weber et al., 2007; Bell et al., 2009; Wolburg et al., 2009).”
BackgroundThe High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Sumter, T. F., Xian, L., Huso, T., Koo, M., Chang, Y.-T., Almasri, T. N., Chia, L., Inglis, C., Reid, D., & Resar, L. M. S. (2016) · Current Molecular Medicine · doi:10.2174/1566524016666160316152147 · Cited by 119
Kitazume, S., Tachida, Y., Kato, M., Yamaguchi, Y., Honda, T., Hashimoto, Y., Wada, Y., Saito, T., Iwata, N., Saido, T., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.144626 · Cited by 120
Endothelial Dysfunction and Amyloid-β-Induced Neurovascular Alterations
Koizumi, K., Wang, G., & Park, L. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0256-9 · Cited by 118
“…the reduced expression of the BBB transporters LRP-1, P-glycoprotein, and PICALM or the increased expression of Mfsda2 in the brain endothelium promotes vascular Ab accumulation and may worsen the vascular dysfunction (Bell et al. 2009; Deane et al. 2003; Zhao et al. 2015; Ben- Zvi et al. 2014).”
Capillary Dysfunction: Its Detection and Causative Role in Dementias and Stroke
Østergaard, L., Jespersen, S. N., Engedahl, T., Jiménez, E. G., Ashkanian, M., Hansen, M. B., Eskildsen, S. F., & Mouridsen, K. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0557-x · Cited by 108
LRP-1 Promotes Cancer Cell Invasion by Supporting ERK and Inhibiting JNK Signaling Pathways
Langlois, B., Perrot, G., Schneider, C., Henriet, P., Emonard, H., Martiny, L., & Dedieu, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011584 · Cited by 102
“including atherosclerosis and neurodegenerative disorders as the most frequently described [4,5].”
BackgroundBiphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
Maki, T., Hayakawa, K., Pham, L.-D. D., Xing, C., Lo, E. H., & Arai, K. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312030004 · Cited by 101
“Pathophysiological levels of A accelerate neuronal [122] and neurovascular [124, 125] dysfunctions, which lead to the development of cerebral -amyloidosis [46].”
BackgroundLi, X., & Buxbaum, J. N. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-79 · Cited by 99
“The majority of clearance occurs via transport through the BBB [73].”
BackgroundHigh-Density Lipoproteins and Cerebrovascular Integrity in Alzheimer’s Disease
Stukas, S. K., Robert, J., & Wellington, C. L. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.003 · Cited by 112
“Bell et al. recently reported that the transactivation of SREBP-2 in AD VSMC resulted in decreased LRP expression and subsequently impaired Ab clearance (Bell et al., 2009).”
BackgroundResveratrol and Amyloid-Beta: Mechanistic Insights
Jia, Y., Wang, N., & Liu, X. (2017) · Nutrients · doi:10.3390/nu9101122 · Cited by 102
“As a cargo transporter, some studies have reported that LRP1 transported several ligands from brain to blood including Aβ [77,78].”
BackgroundTachibana, M., Yamazaki, Y., Liu, C.-C., Bu, G., & Kanekiyo, T. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.023 · Cited by 91
“Deficiency of LRP1 in neurons (Kanekiyo et al., 2013), astrocytes (Liu et al., 2017), endothelial cells (Storck et al., 2016), or vascular smooth muscle cells (Bell et al., 2009; Kanekiyo et al., 2012) has been shown to exacerbate Aβ pathology in mouse models.”
Cerebrovascular disorders: molecular insights and therapeutic opportunities
Storkebaum, E., Quaegebeur, A., Vikkula, M., & Carmeliet, P. (2011) · Nature Neuroscience · doi:10.1038/nn.2947 · Cited by 96
Choi, B.-R., Lee, S. R., Han, J.-S., Woo, S.-K., Kim, K. M., Choi, D.-H., Kwon, K. J., Han, S.-H., Shin, C. Y., Lee, J., et al. (2011) · Stroke · doi:10.1161/strokeaha.111.620179 · Cited by 86
The early contribution of cerebrovascular factors to the pathogenesis of Alzheimer’s disease
Pimentel‐Coelho, P. M., & Rivest, S. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08126.x · Cited by 85
“upregulation of SRF-MYOCD in vascular smooth muscle cells (Bell et al., 2009).”
BackgroundInfluentialQi, X.-M., & Ma, J. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0091-7 · Cited by 92
“Studies have suggested that ApoE4 can block the clearance of soluble Aβ from brain by LRP1 [41], leading to the increasing Aβ deposition in the vascular wall and pathological changes of CAA in APP and ApoE4 double transgenic mice.”
BackgroundInfluentialSagare, A. P., Deane, R., Zetterberg, H., Wallin, A., Blennow, K., & Zlokovic, B. V. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101248 · Cited by 80
“…domain-derived peptides [6] It has been also shown that the cell surface LRP in brain vascular cells provides a major clearance route (cid:1) 3, 7–9], whereas LRP in the liver mediates systemic A (cid:1) clearance [10]. domain of LRP releasing soluble LRP (sLRP) [11] which circulates in plasma…”
Self-citationCastellano, J., Aledo, R., Sendra, J., Costales, P., Juan-Babot, O., Badimon, L., & Llorente-Cortés, V. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.225490 · Cited by 79
Soluble amyloid-β, effect on cerebral arteriolar regulation and vascular cells
Dietrich, H. H., Xiang, C., Han, B. H., Zipfel, G. J., & Holtzman, D. M. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-15 · Cited by 78
“Such accumulation would eventually lead to CAA [32].”
BackgroundInfluentialGSK3 as a Sensor Determining Cell Fate in the Brain
Cole, A. R. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00004 · Cited by 76
“Again, it is not expressed in neurons or glial cells, but interestingly, it is upregulated in vascular smooth muscle cells in the brains of AD patients, where it enhances accumulation of Aβ in blood vessel walls (Bell et al., 2009).”
Prasansuklab, A., & Tencomnao, T. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/413808 · Cited by 75
“In parallel, a study by Bell et al. (2009) reported that hypoxia also causes the impairment of brain clearance of A𝛽 through stimulation of serum response factor (SRF) and myocardin (MYOCD) expressions [91], which were found to be much more active in the blood vessels of brains of people with AD…”
BackgroundCoronary risk correlates with cerebral amyloid deposition
Reed, B. R., Marchant, N. L., Jagust, W. J., DeCarli, C. C., Mack, W., & Chui, H. C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.002 · Cited by 74
“One such potential mechanism would be risk-factor inuced damage to the blood-brain barrier (BBB) (Kalaria, 999), which could result in reduced clearance of A from brain (Bell and Zlokovic, 2009; Bell et al., 2009), and in increased influx of proinflammatory cytokines and other neurotoxins that could themselves amplify…”
BackgroundYan, L., Xie, Y., Satyanarayanan, S. K., Zeng, H., Liu, Q., Huang, M., Ma, Y., Wan, J., Yao, X., Su, K., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.05.033 · Cited by 79
Perrotta, M., Lembo, G., & Carnevale, D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030347 · Cited by 85
“Moreover, in AD patients post mortem tissues and in transgenic mouse models of the pathology [66], a clear alteration of vascular related transcription factors, serum response factor (SRF) and myocardin was found.”
BackgroundCandela, P., Saint‐Pol, J., Kuntz, M., Boucau, M., Lamartinière, Y., Gosselet, F., & Fénart, L. (2014) · Brain Research · doi:10.1016/j.brainres.2014.10.047 · Cited by 87
Metadata
- Authors
- Bell, R. D., Deane, R., Chow, N., Long, X., Sagare, A., Singh, I., Streb, J. W., Guo, H., Rubio, A., Van Nostrand, W., Miano, J. M., & Zlokovic, B. V.
- Affiliations
- University of Rochester Medicine (US)
- Venue
- Nature Cell Biology
- Published
- 2008-12-21
- Volume
- 11
- Issue
- 2
- Pages
- 143-153
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- PMC
- PMC2654279
- OpenAlex
- W2094117787
- Cited by
- 261
- References
- 52
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 10 · 2023: 9 · 2022: 12 · 2021: 10 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 19 · 2016: 12 · 2015: 19 · 2014: 20 · 2013: 17 · 2012: 29
- FWCI
- 14.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Chinese Academy of Agricultural Sciences
- National Institutes of Health
- National Institute on Aging (R37AG023084, R42AG026950, 1R43 AG02400)
- National Heart, Lung, and Blood Institute (R01HL132574, HL 62572, R01HL062572, R01HL091168)
- National Institute of Neurological Disorders and Stroke (R37NS034467, R01NS034467, R37NS34467)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- serum response factor, myocardin, LRP1, amyloid-beta clearance, cerebral amyloid angiopathy, Alzheimer's disease, SREBP2, cerebral hypoxia, transcriptional regulation
- MeSH terms
- Myocardin, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Blood-Brain Barrier, Cells, Cultured, Cerebral Arteries, Disease Models, Animal, Female, Humans, Male, Mice, Transgenic, Muscle, Smooth, Vascular, Nuclear Proteins, Transcriptional Activation, Trans-Activators, Down-Regulation, Amyloid beta-Peptides, Serum Response Factor, Low Density Lipoprotein Receptor-Related Protein-1, Mice, Sterol Regulatory Element Binding Protein 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.